Pediatric Neuromyelitis Optica Spectrum Disorder and Sjögren Syndrome: More Common Than Previously Thought?

SABRINA GMUCA, SCOTT M. LIEBERMAN and JAY MEHTA

J Rheumatol 2017;44;959-960
http://www.jrheum.org/content/44/6/959

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Pediatric Neuromyelitis Optica Spectrum Disorder and Sjögren Syndrome: More Common Than Previously Thought?

To the Editor:

We read with interest the report by Kornitzer, et al in The Journal and agree that increased awareness and a better understanding of the association between pediatric systemic autoimmunity and neuromyelitis optica spectrum disorder (NMOSD) is warranted. In their report, Kornitzer, et al refer to cases previously published by our group as unconfirmed cases of NMOSD because of a lack of NMO immunoglobulin G (IgG) results\(^1\). Here, we provide additional information regarding these cases, as well as 2 new cases to highlight the co-occurrence of childhood Sjögren syndrome (SS) and NMOSD.

The Institutional Review Board approved this study. A waiver of consent/assent was obtained.

Case 1 was an 11-year-old African American girl initially hospitalized for acute transverse myelitis and bilateral optic neuritis in the setting of sicca symptoms. Antinuclear antibody (ANA), SSA, and SSB antibodies were positive. Lip biopsy was consistent with SS (Table 1). Because the patient was diagnosed in 2003, 1 year prior to the discovery of the aquaporin-4 antibody\(^2\), NMO-IgG testing was unavailable. She was readmitted 5 years later with jerking upper extremity movements and altered cognitive speed. Brain magnetic resonance imaging (MRI) revealed interval progression of disease with an enlarged expansile T2 hyperintense lesion extending from T3–T5. Serum NMO-IgG testing was positive. She was treated with intravenous methylprednisolone, rituximab (RTX), cyclophosphamide (CYC), and apheresis. Initial report of this case\(^3\) was prior to her subsequent NMO-IgG testing, and details of her positive NMO-IgG status were not included in subsequent studies that were focused more on childhood SS than on NMOSD\(^4,5\). Thus, case 1 clearly meets diagnostic criteria for NMOSD\(^6\).

Case 2 is a 13-year-old African American girl diagnosed with concomitant SS and NMOSD after presenting with acute visual changes because of left optic neuritis. This case was previously reported in research focused on childhood SS and therefore did not include full details regarding her neurologic course\(^6,7\), which we outline here. She developed blurry vision in her left eye accompanied by pain with left lateral gaze and supraorbital headache. Vision improved after 3 days of methylprednisolone. MRI of the brain and spine showed hyperintensities in the posterior internal capsules on fluid attenuation inversion recovery images. MRI of the cervical and thoracic spine showed expansion and T2 prolongation with a patchy lesion involving the cervical and thoracic spine. Spinal fluid examination showed white blood cell count 600 u/l with 59% lymphocytes, red blood cell count 370 u/l, glucose of 51 mg/dl, and protein of 220 mg/dl. Cerebrospinal antineuronal antibodies were negative and serum NMO-IgG was positive. She had a high-titer ANA and positive SAA and SSB antibodies, along with a lip biopsy demonstrating histopathology characteristic of SS (Table 1). She was initially treated with hydroxychloroquine, glucocorticoids, and CYC, and transitioned to mycophenolate; however, owing to worsening visual symptoms, she received apheresis and RTX.

To identify additional cases of NMOSD and SS, we performed a retrospective chart review at The Children’s Hospital of Philadelphia, Pennsylvania, USA, from May 1, 2001, until January 1, 2016. All patients with the International Classification of Diseases-9-Clinical Modification code for NMO were included. In addition to the 2 aforementioned cases, we identified an additional 2 children with NMOSD who were diagnosed with SS by a pediatric rheumatologist. Case 3 was a 15-year-old African American boy with a history of autism with intractable emesis and hiccups that resolved after empiric treatment with methylprednisolone. He was found to have positive NMO-IgG and demyelinating brain and spinal lesions along with positive ANA, SSA, SSB, and RNP antibodies (Table 1). A lip biopsy was deferred given need for general anesthesia. He was initiated on mycophenolate and RTX for NMOSD and probable SS.

Case 4 was an 11-year-old white boy with a history of encephalitis presenting with blurry vision. NMO-IgG was positive and imaging demonstrated left optic nerve enhancement resulting in a diagnosis of NMOSD. He had positive SSA and ANA antibodies. He had sicca symptoms and mildly reduced salivary pooling. Salivary gland cysts were visualized on ultrasound and a lip biopsy demonstrated chronic sialadenitis and focus score > 0 foci/4 mm\(^2\).

These 4 cases demonstrate the common autoimmune milieu shared between pediatric NMOSD and SS\(^7,8\). Three of the 4 cases had confirmatory lip biopsy results for SS that Kornitzer, et al cite as a distinguishing feature of their case report. However, all our NMOSD cases had positive SSA antibodies highlighting the relationship between NMOSD and SS. Given the lack of validated diagnostic or classification criteria for pediatric SS\(^9,10\), further elucidation of the association between NMOSD and SS may inform future diagnostic criteria for SS. The presence of anti-SSA or SSB antibodies in a child with NMOSD should prompt further evaluation for SS including a biopsy and/or imaging studies to assess for salivary or lacrimal gland inflammation. Similarly, neurologic involvement in pediatric SS should prompt an evaluation for NMOSD.

Table 1. Cases of pediatric NMO spectrum disorder and confirmed or probable SS.

<table>
<thead>
<tr>
<th>Case</th>
<th>SS</th>
<th>Race</th>
<th>Age, Yrs</th>
<th>Sex</th>
<th>SSA, Units*</th>
<th>SSB, Units*</th>
<th>ANA Titer†</th>
<th>NMO-IgG Serum</th>
<th>Salivary Biopsy Findings</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>Confirmed</td>
<td>African American</td>
<td>11</td>
<td>F</td>
<td>108.7</td>
<td>35.5</td>
<td>1:160</td>
<td>Positive</td>
<td>Aggregates of minor salivary glands with several foci of periductal primarily lymphocytic inflammation consistent with SS.</td>
<td>Positive Schirmer test</td>
</tr>
<tr>
<td>#2</td>
<td>Confirmed</td>
<td>African American</td>
<td>13</td>
<td>F</td>
<td>108.9</td>
<td>76.7</td>
<td>≥ 1:1280</td>
<td>Positive</td>
<td>Multiple sections show regional mucous gland lobules exhibiting multiple discrete foci of lymphocytes and plasma cells consistent with SS.</td>
<td>Normal Schirmer test</td>
</tr>
<tr>
<td>#3</td>
<td>Probable</td>
<td>African American</td>
<td>15</td>
<td>M</td>
<td>109.6</td>
<td>68.5</td>
<td>≥ 1:1280</td>
<td>Positive</td>
<td>Deferred given history of autism and need for general anesthesia.</td>
<td>Anti-RNP antibody–positive, 113.9 units*</td>
</tr>
<tr>
<td>#4</td>
<td>Confirmed</td>
<td>White</td>
<td>11</td>
<td>M</td>
<td>158.3</td>
<td>Negative</td>
<td>1:160</td>
<td>Positive</td>
<td>Multiple sections show regional mucous gland lobules exhibiting duct ectasia, acinar degeneration, stromal fibrosis, and an infiltrate of lymphocytes and plasma cells, and focus score &gt; 0 foci/4 mm(^2).</td>
<td>Reduced salivary pooling. Salivary gland cysts visualized on ultrasound.</td>
</tr>
</tbody>
</table>

* Normal range for anti-SSA, anti-SSB, and anti-RNP antibodies based on ELISA testing: 0–19 units. † ANA titer reference range by immunofluorescence testing: 1:20. NMO: neuromyelitis optica; SS: Sjögren syndrome; ANA: antinuclear antibody; IgG: immunoglobulin G.
REFERENCES


